Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD4-IgG · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| CD4-IgG | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Dapsone at a constant dose level and only as a prophylaxis for Pneumocystis carinii pneumonia (PCP). * Zidovudine (AZT) at a constant dose for the 12 weeks of treatment, except if AZT-related toxicity is observed. Patients must have the follow...
CD4-IgG is an investigational small molecule being studied for Immune Thrombocytopenic Purpura (ITP), a hematologic condition. It was evaluated in a Phase 1 clinical trial for patients with HIV-associated ITP. The drug is still in clinical development and is not approved for any use.
CD4-IgG is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company sponsored a Phase 1 study of the drug in patients with HIV-associated Immune Thrombocytopenic Purpura. Roche is the sole developer listed for this asset.
CD4-IgG is in Phase 1 clinical development. One Phase 1 trial, NCT00002250, has been completed. The drug remains investigational and has not received FDA approval. No active trials are currently listed for CD4-IgG.
CD4-IgG has one completed clinical trial, NCT00002250, titled 'A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura.' The study was conducted in the United States and enrolled adults aged 18 years and older.
Yes, CD4-IgG is also known as rCD4-IgG, which stands for recombinant human CD4 immunoglobulin G. The clinical trial NCT00002250 uses this alternative name in its title. Both names refer to the same investigational drug being developed by Roche.